In a push to encourage “personal responsibility,” the Centers for Medicare and Medicaid Services (CMS) has approved work requirements as a condition for receiving Medicaid benefits in four states - Kentucky, Indiana, Arkansas, and most recently New Hampshire, with applications from other states pending. In a new JAMA Viewpoint, Harald Schmidt and Allison Hoffman review the implications and ethics of Medicaid work requirements and other personal responsibility policies. They propose safeguards CMS should consider to minimize risk and protect beneficiaries’ health.
Similar to 23 other states, Pennsylvania requires nurse practitioners to maintain a collaborative practice agreement (CPA) with a physician as a condition of state occupational licensure. In a recent LDI seminar, Dan Gilman, Attorney Advisor of the Federal Trade Commission’s Office of Policy Planning, provided a relevant framework to consider how mandatory CPAs may undermine the delivery of health services to consumers.
Despite professional consensus, guidelines, and national campaigns, physicians continue to provide many low-value services. An emerging policy solution is to financially penalize the physicians who deliver low-value care, but physician support for these policies is largely unknown.
Using a legislatively-mandated, integrated dataset, the Massachusetts Department of Public Health has published its first comprehensive look at the state’s opioid-related overdoses between 2011 and 2015. The dataset links information on an individual level across diverse state databases, including mental health data, jail and prison data, vital records, substance abuse treatment data, and many others. The findings highlight the need to improve treatment access for people who experience a non-fatal overdose, and to tailor treatment to the needs of vulnerable populations.
Prescription drugs are often held as the leading case for a strong patent system: billions of dollars in R&D investment can only be incentivized via ironclad intellectual property protections. With Americans spending over $300 billion annually on prescription drugs, the stakes for incentivizing the right kinds of innovation and paying for value are high. This ongoing work suggests that drugs that rack up patent citations may not be the most innovative, and the most valuable drugs may not be generating the most revenue.
As state legislatures continue to reassess restrictions on the scope of practice of Advanced Practice Registered Nurses (APRNs), Daniel Gilman of the Federal Trade Commission (FTC) will give us his perspectives on how nursing regulations affect competition at the LDI Health Policy seminar on Friday, December 8, 2017 at noon.
In repeated surveys, Americans cite the affordability of health care as their top financial concern. Despite their handwringing, politicians often avoid defining what constitutes “affordable” health care, and both non-experts and seasoned policymakers seem to lack robust measures of affordability. How can the most important crisis in health care lack reliable metrics?
The Food and Drug Administration (FDA) recently approved the first digital pill that tracks if patients have taken their medication. Our experts weighed in on the potential benefits of the new technology, as well as on the potential for abuse.
The Commission on Evidence-Based Policymaking issued a final report in September whose recommendations are rapidly making their way into bipartisan legislation. But there are two harder questions on which the report is silent.
LDI’s 50th Anniversary Symposium convened nearly 450 attendees, including foremost experts in health policy, academia, and industry, to discuss solutions to today's most pressing health care challenges. The two-day event covered topics ranging from innovative population health solutions to redesigning health care delivery and payment. If you missed the dialogue, here are some highlights.